Scarica l'app Stockscreener
6.97
2.65%
-0.19
Precedente Chiudi:
$7.16
Aprire:
$7.16
Volume 24 ore:
759.13K
Relative Volume:
1.09
Capitalizzazione di mercato:
$455.74M
Reddito:
$89.40M
Utile/perdita netta:
$-221.30M
Rapporto P/E:
-2.1404
EPS:
-3.2564
Flusso di cassa netto:
$-256.90M
1 W Prestazione:
-8.77%
1M Prestazione:
-14.58%
6M Prestazione:
-36.64%
1 anno Prestazione:
-28.00%
Intervallo 1D:
$6.925
$7.30
Intervallo di 1 settimana:
$6.74
$7.73
Portata 52W:
$6.74
$14.51
Arvinas Inc Stock (ARVN) Company Profile
Nome
Arvinas Inc
Settore
Industria
Telefono
203-535-1456
Indirizzo
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
6.97 | 455.74M | 89.40M | -221.30M | -256.90M | -3.2564 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-08-04 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-01-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-10-15 | Downgrade | Goldman | Neutral → Sell |
| 2025-09-24 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2025-06-02 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Downgrade | Truist | Buy → Hold |
| 2025-05-02 | Downgrade | Jefferies | Buy → Hold |
| 2025-05-02 | Downgrade | TD Cowen | Buy → Hold |
| 2025-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-03-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2024-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-01 | Iniziato | Goldman | Buy |
| 2023-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-11-20 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-10-23 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-01-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Iniziato | Barclays | Overweight |
| 2022-06-21 | Iniziato | Jefferies | Hold |
| 2022-05-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-04-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2022-01-19 | Iniziato | Goldman | Buy |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-09 | Iniziato | BofA Securities | Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-21 | Iniziato | Truist | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-12-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Perform |
| 2019-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-25 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-25 | Iniziato | Wedbush | Outperform |
| 2019-09-12 | Iniziato | BMO Capital Markets | Outperform |
| 2019-08-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Downgrade | Citigroup | Buy → Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-22 | Iniziato | Citigroup | Buy |
| 2018-10-22 | Iniziato | Goldman | Neutral |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Arvinas Inc Borsa (ARVN) Ultime notizie
KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome - Zacks Investment Research
Reasons Why Investors Should Consider Betting on Arvinas Stock - Zacks Investment Research
TGTX Stock Rises 60% in 6 Months: Here's What You Should Know - Zacks Investment Research
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases - Zacks Investment Research
Arvinas, Inc. (NASDAQ:ARVN) Stock Has Average Price Target of $14.55 - MarketBeat
Arvinas presents phase 1 data for Parkinson’s drug ARV-102 - Investing.com
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease - GlobeNewswire Inc.
Arvinas Shares Novel Oculomotor and Biomarker Data from - GlobeNewswire
Arvinas to present ARV-102 Parkinson’s data at MDS congress - Investing.com
Arvinas to Present Novel Biomarker Data from the Phase 1 - GlobeNewswire
Parkinson’s drug trial data will be presented in a late-breaking oral session - Stock Titan
252,939 Shares in Arvinas, Inc. $ARVN Acquired by Bank of America Corp DE - MarketBeat
Arvinas (NASDAQ:ARVN) Shares Climb 6.3%What's Next? - MarketBeat
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Press Release: Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Arvinas enters immuno-oncology with HPK1 PROTAC degrader in Phase I/II trial - AllSci
Arvinas doses first patient in ARV-6723 cancer trial By Investing.com - Investing.com Nigeria
Arvinas doses first patient in ARV-6723 cancer trial - Investing.com
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate - GlobeNewswire Inc.
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical - GlobeNewswire
A cancer drug designed to remove a protein that limits immune activity enters human testing. - Stock Titan
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate - Yahoo Finance
Arvinas Q2 2026 Earnings Call Transcript - Benzinga
Arvinas (NASDAQ: ARVN) director plans stock sale under SEC resale rule - Stock Titan
Arvinas at 12th Annual Cantor Fitzgerald Global Healthcare Conference: pipeline takes center stage - investing.com
Arvinas at 12th Annual Cantor Fitzgerald Global Healthcare Conference: pipeline takes center stage - Investing.com Canada
Former Arvinas (NASDAQ: ARVN) officer plans new stock sale - Stock Titan
(ARVN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Arvinas (ARVN) Just Made Protein Degrader History With FDA Nod - Yahoo Finance
Arvinas at Wells Fargo conference: pipeline nears key data By Investing.com - Investing.com South Africa
Arvinas at Wells Fargo conference: pipeline nears key data By Investing.com - Investing.com Canada
Arvinas at Wells Fargo conference: pipeline nears key data By Investing.com - Investing.com India
Arvinas (ARVN) Stock Price, News & Analysis - Stock Titan
Former Arvinas (NASDAQ: ARVN) officer lines up new stock sale after recent trades - Stock Titan
Arvinas to Participate in Upcoming Investor Conferences - Yahoo Finance
Arvinas to Participate in Upcoming Investor Conferences - GlobeNewswire
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - globenewswire.com
ARVN Q2 2026 Earnings: EPS of $2.58 Blows Past Consensus; Stock Slips 0.65%Tax Rate Impact - vinanet.vn
The Technical Signals Behind (ARVN) That Institutions Follow - Stock Traders Daily
Arvinas Inc. (ARVN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Arvinas: Veppanu Approval Underlines Degrader Platform PromiseI'm Bullish (NASDAQ:ARVN) - Seeking Alpha
Arvinas (ARVN) Quarterly Results: EPS Lands Above Forecast for the Current Session; Trading Response: Shares Finish 4.54% Higher at the ClosePerformance Review - vinanet.vn
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Arvinas (ARVN) Q2 2026 Filing Snapshot: Reported EPS Tops Expectations at the Close; Price Reaction: Shares Move 0.22% Up in the Current UpdateEPS Growth Report - dars.gov.et
Arvinas (ARVN) Q2 2026 Filing Snapshot: Reported EPS Tops Expectations at the Close; Price Reaction: Shares Move 0.22% Up in the Current UpdateRevenue Miss Report - vinanet.vn
142,214 Shares in Arvinas, Inc. $ARVN Purchased by GSA Capital Partners LLP - MarketBeat
Arvinas Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Arvinas Inc Azioni (ARVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Arvinas Inc Azioni (ARVN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| NOAH C BERKOWITZ | Former Officer |
Sep 09 '26 |
Proposed Sale |
8.84 |
37,200 |
328,915 |
0 |
| NOAH C BERKOWITZ | Former Officer |
Sep 04 '26 |
Proposed Sale |
9.45 |
8,300 |
78,438 |
0 |
| NOAH C BERKOWITZ | Officer |
Aug 04 '26 |
Proposed Sale |
8.80 |
30,000 |
264,000 |
0 |
| NOAH C BERKOWITZ | Former Affiliate |
Jul 09 '26 |
Proposed Sale |
8.40 |
24,000 |
201,528 |
0 |
| Saik Andrew | Chief Financial Officer |
Jun 24 '26 |
Sale |
8.16 |
5,696 |
46,474 |
187,432 |
| Andrew Saik | Officer |
Jun 24 '26 |
Proposed Sale |
8.14 |
5,846 |
47,586 |
0 |
| Cacace Angela M | Chief Scientific Officer |
Jun 17 '26 |
Sale |
7.59 |
2,576 |
19,565 |
180,390 |
| Angela Cacace | Officer |
Jun 17 '26 |
Proposed Sale |
7.42 |
2,642 |
19,604 |
0 |
| Teel Randy | President and CEO |
May 21 '26 |
Sale |
9.04 |
2,209 |
19,962 |
285,009 |
| Randy Teel | Officer |
May 21 '26 |
Proposed Sale |
9.10 |
2,197 |
19,993 |
0 |
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):